natgillin/translations-raw huggingface dataset:
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia.
Incidencija laktacidoze može se i mora smanjiti tako da se u obzir uzmu i ostali povezani faktori rizika poput loše regulacije dijabetesa, ketoze, dugotrajnog gladovanja, prekomjerne konzumacije alkohola, insuficijencije jetre i bilo kojeg stanja povezanog s hipoksijom.
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia.
Incidencija laktacidoze može se i mora smanjiti tako da se u obzir uzmu i ostali čimbenici rizika poput loše kontrole dijabetesa, ketoze, produženog gladovanja, prekomjerne konzumacije alkohola, insuficijencije jetre i svih stanja povezanih s hipoksijom.
The incidence of lactic acidosis can and should be reduced by also assessing other associated risk factors, such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any conditions associated with hypoxia (see also sections 4.3 and 4.5).
Incidencija laktacidoze može se i treba smanjiti procjenom ostalih pridruženih rizičnih čimbenika, kao što su loše regulirana šećerna bolest, ketoza, produženo gladovanje, prekomjerno uzimanje alkohola, insuficijencija jetre i bilo koje stanje povezano s hipoksijom (vidjeti također dijelove 4.3 i 4.5).
The incidence of lactic acidosis can and should be reduced by assessing also other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic insufficiency and any condition associated with hypoxia.
Incidencija laktacidoze može se i treba smanjiti uzimajući u obzir i postojanje drugih čimbenika rizika, kao što su slabo kontrolirana šećerna bolest, ketoza, duže gladovanje, pretjerano konzumiranje alkohola, insuficijencija jetre i svako stanje povezano s hipoksijom.
The incidence of local skin burning was higher in the tacrolimus treatment groups than in the hydrocortisone group.
Incidencija lokalnog žarenja kože bila je veća u skupini liječenoj takrolimusom nego u skupini liječenoj hidrokortizonom.
The incidence of lymphoma (B-cell and T-cell) cases was higher in clinical trials than expected in the general population.
Incidencija slučajeva limfoma (B-stanica i T-stanica) bila je veća u kliničkim ispitivanjima od očekivane incidencije u općoj populaciji.
The incidence of major bleeding is shown in Table 6.
Incidencija velikog krvarenja prikazana je u tablici 6.
The incidence of major bleeding was similar between groups (1.3% versus 1.1% for the clopidogrel + ASA and the placebo + ASA groups, respectively).
Incidencija velikih krvarenja bila je slična u obje skupine.
The incidence of malignancies reported in ustekinumab-treated patients was comparable to the incidence expected in the general population (standardised incidence ratio = 0.87 [95% confidence interval: 0.66, 1.14], adjusted for age, gender and race).
Incidencija malignih bolesti prijavljena kod bolesnika liječenih ustekinumabom bila je usporediva s incidencijom koja se očekuje u općoj populaciji (standardizirani omjer incidencije = 0,87 [95% intervala pouzdanosti: 0,66; 1,14], prilagođeno godinama, spolu i rasi).
The incidence of malignancy in MabThera treated patients in the granulomatosis with polyangiitis and microscopic polyangiitis clinical study was 2.00 per 100 patient years at the study common closing date (when the final patient had completed the follow-up period).
Incidencija zloćudnih bolesti u bolesnika liječenih lijekom MabThera u kliničkom ispitivanju u indikacijama granulomatoze s poliangitisom i mikroskopskog poliangitisa iznosila je 2,00 na 100 bolesnik-godina na dan završetka ispitivanja (kada je posljednji bolesnik dovršio razdoblje praćenja).
The incidence of malignancy in MabThera treated patients in the granulomatosis with polyangiitis and microscopic polyangiitis clinical trial was 2.00 per 100 patient years at the trial common closing date (when the final patient had completed the follow-up period).
Incidencija zloćudnih bolesti u bolesnika liječenih lijekom MabThera u kliničkom ispitivanju u indikacijama granulomatoze s poliangitisom i mikroskopskog poliangitisa iznosila je 2,00 na 100 bolesnik-godina na dan završetka ispitivanja (kada je posljednji bolesnik dovršio razdoblje praćenja).
The incidence of nausea was 24.5% in the lixisenatide group compared to 35.1% in the exenatide twice daily group and the incidence of symptomatic hypoglycaemia with lixisenatide was 2.5% during the 24-week main treatment period compared to 7.9% in the exenatide group.
Incidencija mučnine bila je 24,5% u skupini na liksisenatidu u usporedbi s 35,1% u skupini na eksenatidu dvaput na dan, dok je incidencija simptomatske hipoglikemije tijekom osnovnog tjednog razdoblja liječenja bila 2,5% kod primjene liksisenatida i 7,9% u skupini na eksenatidu.
The incidence of nausea was higher in the lixisenatide group (26.1%) compared to the placebo group (6.2%) and the incidence of vomiting was higher in the lixisenatide group (10.5%) than in the placebo group (1.8%).
Incidencija mučnine bila je viša u skupini liječenoj liksisenatidom (26,1%) nego u skupini koja je primala placebo (6,2%), a incidencija povraćanja bila je viša u skupini liječenoj liksisenatidom (10,5%) nego u skupini koja je primala placebo (1,8%).
The incidence of neutralising antibodies (excluding predose positive patients) was < 1%;
Incidencija neutralizirajućih protutijela (isključujući bolesnike pozitivne prije primjene prve doze) bila je < 1%;
The incidence of neutropenia grade 3 or 4 reported as adverse reactions was higher in multiple myeloma patients receiving MPT (Melphalan, Prednisone, Thalidomide) than in those receiving MP (Melphalan, Prednisone): 42.7% versus 29.5% respectively (study IFM 99-06).
Incidencija neutropenije 3. ili 4. stupnja, prijavljene kao nuspojava, bila je viša u bolesnika s multiplim mijelomom koji su primali MPT (melfalan, prednizon, talidomid) nego u onih koji su primali MP (melfalan, prednizon): 42,7% naspram 29,5% (ispitivanje IFM 99-06).
The incidence of neutropenia was higher in the Gazyvaro plus bendamustine (G+B) arm compared to the bendamustine (B) alone arm (38% and 32%, respectively).
Incidencija neutropenije bila je veća u skupini liječenoj lijekom Gazyvaro plus bendamustinom (G+B) nego u onoj koja je primala samo bendamustin (B) (38% odnosno 32%).
The incidence of non-cutaneous malignancies of various types was significantly higher in patients treated with Enbrel than in the control group.
Incidencija različitih vrsta ne-kožnih zloćudnih bolesti bila je značajno veća kod bolesnika koji su liječeni Enbrelom u odnosu na kontrolnu skupinu.
The incidence of non-melanoma skin cancer was 0.48 per 100 patient-years of follow-up for ustekinumab-treated patients (4 patients in 829 patient-years of follow-up) compared to 0.52 for placebo-treated patients (2 patients in 385 patient-years of follow-up).
Incidencija nemelanomskog raka kože bila je 0,48 na 100 bolesnik-godina praćenja u bolesnika liječenih ustekinumabom (4 bolesnika u 829 bolesnik-godina praćenja) u usporedbi s 0,52 kod bolesnika u placebo grupi (2 bolesnika u 385 bolesnik-godina praćenja).
The incidence of orthostatic hypotension in placebo-controlled clinical studies was 1.2 % with silodosin and 1.0 % with placebo.
Incidencija ortostatske hipotenzije u placebo kontroliranim kliničkim ispitivanjima bila je 1,2 % uz silodozin i 1,0 % uz placebo.
The incidence of orthostatic hypotension in placebo-controlled clinical studies was 1.2 % with silodosin and 1.0 % with placebo.
Incidencija ortostatske hipotenzije u placebom kontroliranim kliničkim ispitivanjima bila je 1,2 % uz silodozin i 1,0 % uz placebo.
The incidence of ovarian cysts may be higher in premenopausal females compared to postmenopausal females.
Incidencija ovarijskih cista može biti viša u žena prije menopauze u usporedbi sa ženama u menopauzi.
The incidence of ovarian cysts may be higher in premenopausal females compared to postmenopausal females.
Incidencija ovarijskih cista može biti viša u žena prije menopauze, u usporedbi sa ženama u menopauzi.
The incidence of patients with triglyceride elevations > 5 x upper limit of normal (ULN) was 2.4% with Ilaris and 0.7% with triamcinolone acetonide.
Incidencija bolesnika s povišenjima triglicerida >5 x gornja granica normale (GGN) bila je 2,4% s Ilarisom i 0,7% s triamcinolon acetonidom.
The incidence of peripheral oedema was lower in the vildagliptin group than in the rosiglitazone group (2.1% vs.
Incidencija perifernog edema bila je niža u skupini koja je primala vildagliptin, nego u skupini koja je primala roziglitazon (2,1%, u odnosu na 4,1%).
The incidence of pneumonia in patients with asthma taking fluticasone furoate/vilanterol 184/22 micrograms was numerically higher compared with those receiving fluticasone furoate/vilanterol 92/22 micrograms or placebo (see section 4.8).
Incidencija pneumonije u bolesnika s astmom koji su uzimali flutikazonfuroat/vilanterol od 184/22 mikrograma bila je brojčano veća u odnosu na bolesnike koji su uzimali flutikazonfuroat/vilanterol od 92/22 mikrograma ili placebo (vidjeti dio 4.8).
The incidence of post-dose symptoms occuring within the first three days after administration of Zoledronic acid Teva Generics can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic acid Teva Generics administration
Incidencija simptoma nakon doze koji se javljaju u roku od prva tri dana nakon primjene zoledronatne kiseline može se smanjiti primjenom paracetamola ili ibuprofena ubrzo nakon primjene zoledronatne kiseline.
The incidence of post-dose symptoms occuring within the first three days after administration of Zoledronic acid Teva Pharma can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic acid Teva Pharma administration
Incidencija simptoma nakon doze koji se javljaju u roku od prva tri dana nakon primjene Zoledronatne kiseline Teva Pharma može se smanjiti primjenom paracetamola ili ibuprofena ubrzo nakon primjene Zoledronatne kiseline Teva Pharma.
The incidence of post-dose symptoms occurring within the first three days after administration of Zoledronic Acid Hospira can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic Acid Hospira administration.
Incidencija simpotma koji se javljaju u prva tri dana nakon primjene doze Zolendronatne kiseline Hospira mogu se smanjiti uzimanjem paracetamola ili ibuprofena nedugo nakon uzimanja Zolendronatne kiseline Hospira.
The incidence of potentially clinically significant decreases in lymphocyte counts (<0.5 x 109/L) (<1%), neutrophil counts (≤1.0 x 109/L) (<1%) and platelet counts (≤100 x 109/L) (≤1%) was similar in Plegridy-treated patients compared to placebo-treated patients.
Incidencija potencijalno klinički značajnog pada broja limfocita (<0,5 x 109/l) (<1%), broja neutrofila (≤ 1,0 x 109/l) (<1%), i broja trombocita (≤ 100 x 109/l) (≤ 1%) je bila slična u bolesnika liječenih Plegridyjem u odnosu na bolesnike koji su primali placebo.
The incidence of pre- existing antibodies to romiplostim and TPO was 8.0% and 5.4%, respectively.
Incidencija od prije postojećih protutijela na romiplostim i TPO je bila 8,0%, odnosno 5,4%.
The incidence of pregnancy loss by miscarriage or abortion is higher in patients undergoing stimulation of follicular growth for ovulation induction or ART than following natural conception.
Incidencija gubitka trudnoće bilo u vidu spontanog pobačaja ili prekida trudnoće veća je u pacijentica kod kojih se provodi stimulacija rasta folikula za indukciju ovulacije ili za metode medicinski potpomognute oplodnje u odnosu na prirodno začeće.
The incidence of pregnancy loss by miscarriage or abortion is higher in patients undergoing stimulation of follicular growth for ovulation induction or ART than following natural conception.
Incidencija gubitka trudnoće bilo u vidu spontanog pobačaja ili prekida trudnoće veća je u pacijentica kod kojih se provodi stimulacija rasta folikula za indukciju ovulacije ili za metode medicinski potpomognute reprodukcije u odnosu na prirodno začeće.
The incidence of rash was higher in women compared to men in the INTELENCE arm in the DUET trials (rash ≥ grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) (see section 4.4).
U ispitivanjima DUET incidencija osipa bila je veća kod žena nego kod muškaraca u skupini koja je primala INTELENCE (osip ≥ stupanj 2 bio je prijavljen u 9/60 [15,0%] žena naspram 51/539 [9,5%] muškaraca; prekidi zbog osipa bili su prijavljeni u 3/60 [5,0%] žena naspram 10/539 [1,9%] muškaraca) (vidjeti dio 4.4).
The incidence of relapse during the 6- months double-blind follow-up period was 14% for Xeristar and 42% for placebo.
Incidencija relapsa tijekom 6-mjesečnog razdoblja dvostruko slijepog praćenja iznosila je 14% u bolesnika koji su uzimali Xeristar i 42% u onih koji su uzimali placebo.
The incidence of relapse during the 6-months double-blind follow up period was 22% and 47% for Thymanax and placebo, respectively.
Incidencija recidiva tijekom 6-mjesečnog dvostruko slijepog praćenja bila je 22% za Thymanax, a 47% za placebo.
The incidence of relapse during the 6-months double-blind follow up period was 22% and 47% for Valdoxan and placebo, respectively.
Incidencija recidiva tijekom 6- mjesečnog dvostruko slijepog praćenja bila je 22% za Valdoxan, a 47% za placebo.
The incidence of relapse during the 6-months double-blind follow-up period was 14% for duloxetine and 42% for placebo.
Incidencija relapsa tijekom 6-mjesečnog razdoblja dvostruko slijepog praćenja iznosila je 14% u bolesnika koji su uzimali lijek Cymbalta i 42% u onih koji su uzimali placebo.
The incidence of relapse during the 6-months double-blind follow-up period was 14% for Duloxetine Lilly and 42% for placebo.
Incidencija relapsa tijekom 6-mjesečnog razdoblja dvostruko slijepog praćenja iznosila je 14% u bolesnika koji su uzimali lijek Duloksetin Lilly i 42% u onih koji su uzimali placebo.
The incidence of resistance to caspofungin by various clinical isolates of Candida and Aspergillus is rare.
Incidencija rezistencije različitih kliničkih izolata rodova Candida i Aspergillus na kaspofungin je rijetka.
The incidence of retinal detachment that occurred pre-vitrectomy was 0.4% in the JETREA group and none in the placebo group, while the incidence of retinal tears (without detachment) that occurred pre-vitrectomy was 0.2% in the JETREA group and 0.5% in the placebo group.
Incidencija odignuća mrežnice, koje su se dogodile prije vitrektomije, iznosila je 0,4% u skupini koja je primila injekciju JETREE i nula u onoj koja je primila injekciju placeba, dok je incidencija ruptura mrežnice (bez ablacije), koje su se dogodile prije vitrektomije, iznosila 0,2% u skupini koja je primila injekciju JETREE i 0,5% u onoj koja je primila placebo.
The incidence of seizure events was low and comparable in patients receiving Plegridy (125 micrograms every 2 weeks) and placebo (<1% in each group).
Incidencija događaja epileptičkog napadaja je bila niska i usporediva u bolesnika koji su dobivali Plegridy (125 mikrograma svaka 2 tjedna) i bolesnika koji su dobivali placebo (<1% u svakoj skupini).
The incidence of seizure events was low and comparable in patients receiving Plegridy (125 micrograms every 2 weeks) and placebo (<1% in each group).
Incidencija događaja epileptičkog napadaja je bila niska i usporediva u bolesnika koji su dobivali Plegridy (125 mikrograma svaka 2 tjedna) i bolesnika koji su dobivali placebo (≤ 1% u svakoj skupini).
The incidence of serious adverse events was higher in older people compared to younger patients.
Incidencija ozbiljnih nuspojava bila je veća u starijih osoba u odnosu na mlađe osobe.
The incidence of serious adverse events was higher in older people compared to younger patients.
Incidencija ozbiljnih nuspojava bila je veća u starijih osoba u odnosu na mlađe.
The incidence of serious adverse events was higher in the older people compared to younger patients.
Incidencija ozbiljnih nuspojava bila je veća u starijih osoba u odnosu na mlađe.
The incidence of serious adverse events was higher in the older people patients compared to younger patients.
Incidencija ozbiljnih nuspojava bila je veća u starijih osoba u odnosu na mlađe bolesnike.
The incidence of serious adverse reactions that occurred in all clinical studies was 2.2% in JETREA treated patients and 2.4% in control patients.
Učestalost ozbiljnih nuspojava koje su se javljale u svim kliničkim ispitivanjima iznosila je 2,2% u ispitanika koji su primali JETREU, a 2,4% u kontrolnih ispitanika.
The incidence of serious bleeding events was higher in patients with AP-CML, BP-CML and Ph+ ALL.
Incidencija događaja ozbiljnog krvarenja bila je viša u bolesnika s AP-KML, BP- KML, i Ph+ ALL.
The incidence of serious events related to depression and suicidal ideation were similar and low (<1%) in both Plegridy 125 micrograms every 2 weeks and placebo-treated patients.
Incidencija ozbiljnih događaja vezanih uz depresiju i suicidalne ideacije bila je slična i niska (<1%) za obje skupine, skupinu koja je dobivala 125 mikrograma Plegridyja svaka 2 tjedna i placebo skupinu.
The incidence of serious flushing, which may be characterised by generalised erythema, rash and/or pruritus, was seen in less than 1% of patients treated with Tecfidera (see sections 4.2, 4.4 and 4.5).
Incidencija ozbiljnog crvenila uz osjećaj vrućine, koje se može karakterizirati kao generalizirani eritem, osip i/ili pruritus, javila se u manje od 1% bolesnika liječenih Tecfiderom (vidjeti dijelove 4.2, 4.4 i 4.5).
The incidence of serious gastrointestinal events, including gastroenteritis and gastritis, was seen in 1% of patients treated with Tecfidera (see section 4.2).
Incidencija ozbiljnih gastrointestinalnih smetnji, uključujući gastroenteritis i gastritis, primijećena je u 1% bolesnika liječenih Tecfiderom (vidjeti dio 4.2).
The incidence of serious infections in RA studies conducted at the recommended dose (100 mg/day) was 1.8% in Kineret treated patients and 0.7% in placebo-treated patients.
Incidencija ozbiljnih infekcija u ispitivanjima koja su provedena u bolesnika s RA pri preporučenoj dozi (100 mg/dan) iznosila je 1,8% u bolesnika liječenih Kineretom te 0,7% u bolesnika liječenih placebom.
The incidence of severe cases was 1.4% for clopidogrel and 1.6% for ASA.
Incidencija teških slučajeva bila je slična za klopidogrel i ASK.
The incidence of severe haemorrhagic events (Grade ≥ 3) was 2.1% in cabozantinib-treated RCC patients (7/331).
Incidencija teških hemoragijskih događaja (≥ 3. stupanj) bila je 2,1 % u bolesnika s RCC-om liječenih kabozantinibom.
The incidence of severe haemorrhagic events (Grade ≥3) occurred in 2.2% of the overall trastuzumab emtansine treated patients and 1.8% of Asian trastuzumab emtansine treated patients.
Incidencija teških događaja krvarenja (stupnja ≥ 3) iznosila je 2,2% u svih bolesnika liječenih trastuzumab emtanzinom te 1,8% u bolesnika azijskog podrijetla koji su primali trastuzumab emtanzin.
The incidence of severe headache, severe dizziness, and severe insomnia was low, but was higher in subjects treated with naltrexone / bupropion compared to subjects treated with placebo (severe headache: naltrexone / bupropion 1.1%, placebo 0.3%; severe dizziness: naltrexone / bupropion 0.6%, placebo 0.2%; severe insomnia: naltrexone / bupropion 0.4%, placebo <0.1%).
Incidencija teške glavobolje, teške omaglice, i teške nesanice je bila niska, ali je bila viša u ispitanika liječenih naltrekson / bupropionom u odnosu na ispitanike koji su primali placebo (teška glavobolja: naltrekson / bupropion 1,1 %, placebo 0,3 %; teška omaglica: naltrekson / bupropion 0,6 %, placebo 0,2 %; teška nesanica: naltrekson / bupropion 0,4 %, placebo < 0,1 %).
The incidence of severe local skin responses that occurred at an incidence >1% in both the ‘face/scalp’ and the ‘trunk/extremities’, respectively are: application site erythema (24% and 15%), application site exfoliation (9% and 8%), application site scab (6% and 4%), application site swelling (5% and 3%) and application site pustules (5% and 1%).
Teške lokalne kožne reakcije koje su se pojavile pri incidenciji od >1% na “licu/vlasištu”, odnosno na “trupu/udovima” bile su: eritem na mjestu primjene (24% i 15%), ljuštenje na mjestu primjene (9% i 8%), krasta na mjestu primjene (6% i 4%), oticanje na mjestu primjene (5% i 3%) i gnojni mjehurići na mjestu primjene (5% i 1%).
The incidence of severe or life threatening bleeding events with Integrilin was 1.9% compared to 1.1% with placebo.
Incidencija teških i po život opasnih krvarenja u bolesnika koji su dobivali INTEGRILIN bila je 1,9 % u usporedbi s 1,1 % bolesnika koji su dobivali placebo.
The incidence of side effects after topical ophthalmic administration is lower than when medicines are, for example, taken by mouth or injected.
Incidencija nuspojava nakon lokalne primjene lijeka u oko niža je nego kada se lijekovi uzimaju kroz usta ili u venu.
The incidence of skin laceration (29.1%) was higher for subjects treated with two concurrent injections of Xiapex in historically-controlled clinical study AUX-CC-867 compared with subjects treated with up to three single injections in the Phase 3 placebo-controlled pivotal studies in Dupuytren’s contracture (CORD I and CORD II) (8.8%).
Incidencija laceracije kože (29,1%) bila je viša u ispitanika koji su istovremeno primili dvije injekcije Xiapexa u ispitivanju AUX-CC-867 u kojem se koristila kontrolna skupina iz prošlosti u usporedbi s ispitanicima koji su primili do tri jednokratne injekcije u placebom kontroliranim ključnim ispitivanjima faze III (CORD I i CORD II) kod Dupuytrenove kontrakture (8,8%).
The incidence of some dopaminergic adverse reactions, such as hallucinations, dyskinesia, and peripheral oedema generally is higher when given in combination with L-dopa in Parkinson’s patients.
Incidencija nekih dopaminergičkih neželjenih događaja, kao što su halucinacije, diskinezija i periferni edemi, općenito je veća kod istovremene primjene s levodopom u bolesnika s Parkinsonovom bolešću.
The incidence of some dopaminergic adverse reactions, such as hallucinations, dyskinesia, and peripheral oedema generally is higher when given in combination with L-dopa in Parkinson’s patients.
Incidencija nekih dopaminergičkih nuspojava, kao što su halucinacije, diskinezija i periferni edemi, općenito je veća kod istovremene primjene s levodopom u bolesnika s Parkinsonovom bolešću.
The incidence of somnolence is increased at doses higher than 1.5 mg/day (see section 4.2).
Incidencija somnolencije povećava se pri dozama višim od 1,5 mg na dan (vidjeti dio 4.2).
The incidence of squamous cell papilloma and carcinoma in the nonglandular stomach (forestomach) was increased at equivalent exposure to the recommended human dose in mice and below exposure to the recommended human dose in rats (based on AUC).
Incidencija papiloma skvamoznih stanica i karcinoma nežljezdanog želuca (predželuca) bila je povećana pri ekvivalentnoj izloženosti preporučene ljudske doze u miševa i ispod izloženosti preporučene ljudske doze u štakora (na temelju AUC).
The incidence of subjects with at least 1 treatment-emergent adverse event (TEAE) was similar between the Resolor treatment group (69.8%) and the placebo treatment group (60.7%).
Incidencija ispitanika s najmanje 1 štetnim događajem izazvanim liječenjem bila je slična kod skupine liječene lijekom Resolor (69,8%) i skupine liječene placebom (60,7%).
The incidence of symptomatic cardiac dysfunction was 1.7% in the Herceptin arm.
Incidencija simptomatske disfunkcije srca u skupini koja je primala Herceptin iznosila je 1,7%.